التفاصيل البيبلوغرافية
| العنوان: |
Clinical and prognostic associations of autoantibodies recognizing adrenergic/muscarinic receptors in patients with heart failure. |
| المؤلفون: |
Markousis-Mavrogenis, George1 (AUTHOR), Minich, Waldemar B2,3 (AUTHOR), Al-Mubarak, Ali A1 (AUTHOR), Anker, Stefan D4 (AUTHOR), Cleland, John G F5,6 (AUTHOR), Dickstein, Kenneth7 (AUTHOR), Lang, Chim C8 (AUTHOR), Ng, Leong L9,10 (AUTHOR), Samani, Nilesh J7 (AUTHOR), Zannad, Faiez11 (AUTHOR), Metra, Marco12 (AUTHOR), Seemann, Petra2,3 (AUTHOR), Hoeg, Antonia2 (AUTHOR), Lopez, Patricio2,3 (AUTHOR), Veldhuisen, Dirk J van1 (AUTHOR), Boer, Rudolf A de1 (AUTHOR), Voors, Adriaan A1 (AUTHOR), van der Meer, Peter1 (AUTHOR), Schomburg, Lutz2 (AUTHOR) lutz.schomburg@charite.de, Bomer, Nils1 (AUTHOR) |
| المصدر: |
Cardiovascular Research. 6/15/2023, Vol. 119 Issue 8, p1690-1705. 16p. |
| مصطلحات موضوعية: |
*MUSCARINIC receptors, *HEART failure patients, *AUTOANTIBODIES, *CHRONIC obstructive pulmonary disease, *CHEMILUMINESCENCE immunoassay |
| مستخلص: |
Aims The importance of autoantibodies (AABs) against adrenergic/muscarinic receptors in heart failure (HF) is not well-understood. We investigated the prevalence and clinical/prognostic associations of four AABs recognizing the M2-muscarinic receptor or the β1-, β2-, or β3-adrenergic receptor in a large and well-characterized cohort of patients with HF. Methods and results Serum samples from 2256 patients with HF from the BIOSTAT-CHF cohort and 299 healthy controls were analysed using newly established chemiluminescence immunoassays. The primary outcome was a composite of all-cause mortality and HF rehospitalization at 2-year follow-up, and each outcome was also separately investigated. Collectively, 382 (16.9%) patients and 37 (12.4%) controls were seropositive for ≥1 AAB (P = 0.045). Seropositivity occurred more frequently only for anti-M2 AABs (P = 0.025). Amongst patients with HF, seropositivity was associated with the presence of comorbidities (renal disease, chronic obstructive pulmonary disease, stroke, and atrial fibrillation) and with medication use. Only anti-β1 AAB seropositivity was associated with the primary outcome [hazard ratio (95% confidence interval): 1.37 (1.04–1.81), P = 0.024] and HF rehospitalization [1.57 (1.13–2.19), P = 0.010] in univariable analyses but remained associated only with HF rehospitalization after multivariable adjustment for the BIOSTAT-CHF risk model [1.47 (1.05–2.07), P = 0.030]. Principal component analyses showed considerable overlap in B-lymphocyte activity between seropositive and seronegative patients, based on 31 circulating biomarkers related to B-lymphocyte function. Conclusions AAB seropositivity was not strongly associated with adverse outcomes in HF and was mostly related to the presence of comorbidities and medication use. Only anti-β1 AABs were independently associated with HF rehospitalization. The exact clinical value of AABs remains to be elucidated. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder